# TABLE OF CONTENTS

*FOREWORD BY PHILIP KOTLER*  
XI  

*PREFACE*  
XIII  

*ACKNOWLEDGMENTS*  
XVII  

*ABOUT THE AUTHORS*  
XIX  

## PART 1  NEW MODELS FOR NETWORKED INNOVATION

### CHAPTER 1  DIGITAL EVOLUTION OF BIOTECHNOLOGY  
3  
- Industry Applications  
- Impact of Megatrends  
- Digital Health Opportunities  
- Infotechnology Initiatives in Healthcare  
- Disruption Risk from Infotech  
- Technology Strategies  
- Big Infotech Strategies  
- Conclusion  
- Summary Points

### CHAPTER 2  BIOTECHNOLOGY FINANCING STRATEGIES  
24  
- The Long Game  
- Financing Strategies for the Long Term at Alnylam  
- Strategic Decisions  
- Geographic Considerations  
- Sources of Financing  
- A Word about Mergers and Acquisitions  
- Summary Points

### CHAPTER 3  SUCCESS THROUGH COLLABORATION  
46  
- Alliance Evolution: More Players and New Structures  
- Strategic Alliances: A Stalwart of the Biopharma Industry
### TABLE OF CONTENTS

#### CHAPTER 6   **PATIENT CENTRICITY STRATEGIES**

- Introduction   120
- Patient Centricity Drivers and Barriers   121
- Discovery: Understanding Unmet Needs   123
- Designing Patient-Friendly Clinical Trials   125
- Connecting the Points of Care   130
- Understanding the Patient Journey   135
- Organizing for Patient Centricity   138
- Who Are You Working For? Bristol-Myers Squibb Employee Engagement Initiative   138
- Patient Engagement Metrics   140
- Organization Models   142
- Summary Points   143

#### CHAPTER 7   **DRUG PRICING IN CONTEXT**

- Introduction   145
- The Economics of Drug Pricing   146
- Competing Definitions of Product Value Complicate Drug Pricing   153
- Proving Efficacy in the Real World   155
- Setting the Pricing Strategy   157
- Analyzing New Pricing Models   160
- Drug Pricing in the United States: The Pressure Continues to Build   162
- Deployment of New Pricing Strategies   163
- Experimental Pricing Strategies   165
- Financing the Future: Affordability   169
- New Tools for Outcomes-Data Capture   170
- Conclusion   171
- Summary Points   171

#### CHAPTER 8   **STRATEGIC PAYER ENGAGEMENT**

- Payers Are Not All Alike   173
- New Market Forces Increase Payer Power   175
- The Increasing Importance of the Consumer in the United States   176
- European Payers: High-Level Unity, Low-Level Fragmentation   180
- United States Adopts European-Style Cost-Effectiveness Hurdles   181
- Payer Engagement Strategies Must be Tailored, Scalable, and Flexible   182
- Changing Biopharma-Payer Relationships: From Transactional to Collaborative   185
- New Biopharma Organizational Models Needed   187
- Biopharma-Payer Engagement Must Move Beyond Experimentation   188
- Strategic Payer Engagement Comes in Many Forms   192
- Summary Points   193
PART 3  NEW MODELS FOR DIGITAL HEALTH

CHAPTER 9  DIGITAL HEALTH STRATEGIES  197

Introduction  197
Biopharma Digital Strategies  197
Digital Impact on Supply Chain Management  200
Digital Transformation of Commercial Activities  201
Consumer-Centered Trends  206
Provider-Centered Strategies: Telehealth  210
Conclusion  213
Summary Points  213

CHAPTER 10  CREATING AGILITY THROUGH DATA AND ANALYTICS  215

Introduction  215
Multiple Forces Converge to Create Data and Analytics Opportunities  216
Healthcare’s Four Data Vectors: Volume, Velocity, Variety, and Veracity  218
Extracting Value from Data Requires New Tools  221
The Analytics Continuum: From Descriptive to Prescriptive  223
Artificial Intelligence: The Potential to Make Drugs Smarter, Faster, and for Less  225
Data Analytics across the Biopharma Value Chain  226
Data and Analytics Challenges  233
Building an Analytics-First Organization: Cultural not Technical Hurdles  238
Conclusion  242
Summary Points  242

CONCLUSION  243
REFERENCES  246
INDEX  273